Australia - English - Department of Health (Therapeutic Goods Administration)

azure health products pty ltd - silybum marianum, quantity: 500 mg (equivalent: silybum marianum, qty 35 g; equivalent: silymarin, qty 400 mg); cyanocobalamin, quantity: 1 mg; riboflavin, quantity: 50 mg; sugar cane wax alcohols, quantity: 12 mg - capsule, hard - excipient ingredients: gelatin; magnesium stearate; colloidal anhydrous silica; microcrystalline cellulose; purified water; sodium lauryl sulfate - maintain/support natural liver cleansing/detoxification processes ; maintain/support energy production ; helps enhance/promote general health and wellbeing ; maintain/support general health and wellbeing ; aid/assist healthy red blood cell production ; helps maintain/support healthy cholesterol ; maintain/support healthy digestive system function ; maintain/support healthy liver function ; maintain/support healthy immune system function ; helps enhance/promote skin health ; maintain/support skin health

Australia - English - Department of Health (Therapeutic Goods Administration)

azure health products pty ltd - alpha lipoic acid, quantity: 100 mg; calcium pantothenate, quantity: 10 mg (equivalent: pantothenic acid, qty 9.2 mg); chromium picolinate, quantity: 1.77 mg (equivalent: chromium, qty 0.22 mg); cyanocobalamin, quantity: 0.02 mg; folic acid, quantity: 0.095 mg; gymnema sylvestre, quantity: 125 mg (equivalent: gymnema sylvestre, qty 2 g); nicotinamide, quantity: 20 mg; cinnamomum cassia, quantity: 50 mg (equivalent: cinnamomum cassia, qty 500 mg; equivalent: coumarin, qty 2.5 microgram); momordica charantia, quantity: 100 mg (equivalent: momordica charantia, qty 1 g); pyridoxine hydrochloride, quantity: 15 mg (equivalent: pyridoxine, qty 12.34 mg); riboflavin, quantity: 7.5 mg; thiamine hydrochloride, quantity: 5 mg - capsule, hard - excipient ingredients: magnesium stearate; microcrystalline cellulose; maltodextrin; calcium hydrogen phosphate dihydrate; silicon dioxide; gelatin; purified water - maintain/support energy production ; helps enhance/promote general health and wellbeing ; maintain/support general health and wellbeing ; helps maintain/support healthy blood sugar/glucose ; aid/assist/helps in the management of sugar cravings

Australia - English - Department of Health (Therapeutic Goods Administration)

azure health products pty ltd - verbascum thapsus, quantity: 150 mg (equivalent: verbascum thapsus, qty 600 mg); astragalus membranaceus, quantity: 100 mg (equivalent: astragalus membranaceus, qty 1 g); andrographis paniculata, quantity: 75 mg (equivalent: andrographis paniculata, qty 1.05 g); thymus vulgaris, quantity: 50 mg (equivalent: thymus vulgaris, qty 200 mg); ganoderma lucidum, quantity: 50 mg (equivalent: ganoderma lucidum, qty 1 g); retinol palmitate, quantity: 350 microgram (equivalent: vitamin a, qty 191.05 re); selenomethionine, quantity: 0.01 mg (equivalent: selenium, qty 0.004 mg); calcium ascorbate dihydrate, quantity: 121.07 mg (equivalent: ascorbic acid, qty 100 mg) - tablet, film coated - excipient ingredients: microcrystalline cellulose; acacia; silicon dioxide; maltodextrin; dextrin; sucrose; maize starch; butylated hydroxytoluene; calcium hydrogen phosphate; hypromellose; calcium hydrogen phosphate dihydrate; magnesium stearate; croscarmellose sodium; crospovidone; povidone; macrogol 400; chlorophyllin-copper complex; titanium dioxide; carnauba wax - helps enhance/promote general health and wellbeing ; maintain/support general health and wellbeing ; maintain/support immune system health ; maintain/support (state vitamin/mineral/nutrient) levels in the body ; maintain/support lung health

Australia - English - Department of Health (Therapeutic Goods Administration)

azure health products pty ltd - nicotinamide mononucleotide, quantity: 150 mg - tablet, film coated - excipient ingredients: calcium hydrogen phosphate dihydrate; microcrystalline cellulose; crospovidone; croscarmellose sodium; povidone; magnesium stearate; colloidal anhydrous silica; hypromellose; macrogol 400; titanium dioxide; carnauba wax

Australia - English - Department of Health (Therapeutic Goods Administration)

medtronic australasia pty ltd - 47267 - single-chamber pacemaker, rate-responsive - the azure s sr mri surescan model w3sr01 single chamber implantable pulse generator (ipg) is a multi-programmable cardiac device that monitors and regulates the patient?s heart rate by providing single chamber rate-responsive bradycardia pacing. this device features bluetooth wireless technology. the azure s sr mri surescan system is indicated for use in patients who may benefit from rate responsive or non-rate responsive pacing to restore physiologic heart rates, improve cardiac output, prevent symptoms, or protect against arrhythmias related to cardiac impulse formation or conduction disorders

Australia - English - Department of Health (Therapeutic Goods Administration)

medtronic australasia pty ltd - 47267 - single-chamber pacemaker, rate-responsive - the azure xt sr mri surescan model w2sr01 single chamber implantable pulse generator (ipg) is a multi-programmable cardiac device that monitors and regulates the patient?s heart rate by providing single chamber rate-responsive bradycardia pacing. this device features bluetooth wireless technology. the azure xt sr mri surescan system is indicated for use in patients who may benefit from rate responsive or non-rate responsive pacing to restore physiologic heart rates, improve cardiac output, prevent symptoms, or protect against arrhythmias related to cardiac impulse formation or conduction disorders.

Australia - English - Department of Health (Therapeutic Goods Administration)

medtronic australasia pty ltd - 47265 - dual-chamber pacemaker, rate-responsive - the azure s dr mri surescan model w3dr01 dual chamber implantable pulse generator (ipg) is a multi-programmable cardiac device that monitors and regulates the patient?s heart rate by providing single or dual chamber rate-responsive bradycardia pacing. this device features bluetooth wireless technology. the azure s dr mri surescan system is indicated for use in patients who may benefit from rate responsive or non-rate responsive pacing to restore physiologic heart rates, improve cardiac output, prevent symptoms, or protect against arrhythmias related to cardiac impulse formation or conduction disorders.

Australia - English - Department of Health (Therapeutic Goods Administration)

medtronic australasia pty ltd - 47265 - dual-chamber pacemaker, rate-responsive - the medtronic azure xt dr mri surescan model w2dr01 dual chamber implantable pulse generator (ipg) is a multi-programmable cardiac device that monitors and regulates the patient?s heart rate by providing single or dual chamber rate-responsive bradycardia pacing and atrial tachyarrhythmia therapies. this device features bluetooth wireless technology. the azure xt dr mri surescan system is indicated for use in patients who may benefit from rate responsive or non-rate responsive pacing to restore physiologic heart rates, improve cardiac output, prevent symptoms, or protect against arrhythmias related to cardiac impulse formation or conduction disorders.

Australia - English - Department of Health (Therapeutic Goods Administration)

medtronic australasia pty ltd - 47265 - dual-chamber pacemaker, rate-responsive - the azure s dr mri surescan model w3dr01 dual chamber implantable pulse generator (ipg) is a multi-programmable cardiac device that monitors and regulates the patient?s heart rate by providing single or dual chamber rate-responsive bradycardia pacing. this device features bluetooth wireless technology. the medtronic azure s dr mri surescan model w3dr01 implantable pulse generator (ipg) is indicated for the following conditions: ? accepted patient conditions warranting chronic cardiac pacing, which include: ? paroxysmal or permanent type 2 second- or third-degree av block ? symptomatic type 1 second-degree av block or block located at intra- or infra-his levels, regardless of symptoms ? symptomatic paroxysmal or transient sinus node dysfunctions with or without associated av conduction disorders ? bradycardia-tachycardia syndrome to prevent symptomatic bradycardia or some forms of symptomatic tachyarrhythmias ? alternating bundle branch block ? bundle branch block with unexplained syncope and abnormal eps or non-diagnostic evaluation ? rate adaptive pacing in patients who may benefit from increased pacing rates concurrent with increases in activity. this device is also indicated for dual chamber and atrial tracking modes in patients who may benefit from maintenance of av synchrony. dual chamber modes are specifically indicated for treatment of conduction disorders that require restoration of both rate and av synchrony, which include: ? various degrees of av block to maintain the atrial contribution to cardiac output ? vvi intolerance (for example, pacemaker syndrome) in the presence of persistent sinus rhythm ? vasovagal syndromes or hypersensitive carotid sinus syndromes

Australia - English - Department of Health (Therapeutic Goods Administration)

medtronic australasia pty ltd - 47267 - single-chamber pacemaker, rate-responsive - the azure s sr mri surescan model w3sr01 single chamber implantable pulse generator (ipg) is a multi-programmable cardiac device that monitors and regulates the patient?s heart rate by providing single chamber rate-responsive bradycardia pacing. this device features bluetooth wireless technology. the medtronic azure s sr mri surescan model w3sr01 implantable pulse generator (ipg) is indicated for the following conditions: ? accepted patient conditions warranting chronic cardiac pacing, which include: ? paroxysmal or permanent type 2 second- or third-degree av block ? symptomatic type 1 second-degree av block or block located at intra- or infra-his levels, regardless of symptoms ? symptomatic paroxysmal or transient sinus node dysfunctions with or without associated av conduction disorders ? bradycardia-tachycardia syndrome to prevent symptomatic bradycardia or some forms of symptomatic tachyarrhythmias ? alternating bundle branch block ? bundle branch block with unexplained syncope and abnormal eps or non-diagnostic evaluation ? rate adaptive pacing in patients who may benefit from increased pacing rates concurrent with increases in activity.